-
World record-holders Walsh, Smith grab wins at US Open
-
Ukraine, US to meet for third day, agree 'real progress' depends on Russia
-
Double wicket strike as New Zealand eye victory over West Indies
-
Peace medal and YMCA: Trump steals the show at World Cup draw
-
NBA legend Jordan in court as NASCAR anti-trust case begins
-
How coaches reacted to 2026 World Cup draw
-
Glasgow down Sale as Stomers win at Bayonne in Champions Cup
-
Trump takes aim at Europe in new security strategy
-
Witness in South Africa justice-system crimes probe shot dead
-
Tuchel urges England not to get carried away plotting route to World Cup glory
-
Russian ambassador slams EU frozen assets plan for Ukraine
-
2026 World Cup draw is kind to favorites as Trump takes limelight
-
WHO chief upbeat on missing piece of pandemic treaty
-
US vaccine panel upends hepatitis B advice in latest Trump-era shift
-
Ancelotti says Brazil have 'difficult' World Cup group with Morocco
-
Kriecmayr wins weather-disrupted Beaver Creek super-G
-
Ghostwriters, polo shirts, and the fall of a landmark pesticide study
-
Mixed day for global stocks as market digest huge Netflix deal
-
Fighting erupts in DR Congo a day after peace deal signed
-
England boss Tuchel wary of 'surprise' in World Cup draw
-
10 university students die in Peru restaurant fire
-
'Sinners' tops Critics Choice nominations
-
Netflix's Warner Bros. acquisition sparks backlash
-
France probes mystery drone flight over nuclear sub base
-
Frank Gehry: five key works
-
US Supreme Court to weigh Trump bid to end birthright citizenship
-
Frank Gehry, master architect with a flair for drama, dead at 96
-
'It doesn't make sense': Trump wants to rename American football
-
A day after peace accord signed, shelling forces DRC locals to flee
-
Draw for 2026 World Cup kind to favorites as Trump takes center stage
-
Netflix to buy Warner Bros. in deal of the decade
-
US sanctions equate us with drug traffickers: ICC dep. prosecutor
-
Migration and crime fears loom over Chile's presidential runoff
-
French officer charged after police fracture woman's skull
-
Fresh data show US consumers still strained by inflation
-
Eurovision reels from boycotts over Israel
-
Trump takes centre stage as 2026 World Cup draw takes place
-
Trump all smiles as he wins FIFA's new peace prize
-
US panel votes to end recommending all newborns receive hepatitis B vaccine
-
Title favourite Norris reflects on 'positive' Abu Dhabi practice
-
Stocks consolidate as US inflation worries undermine Fed rate hopes
-
Volcanic eruptions may have brought Black Death to Europe
-
Arsenal the ultimate test for in-form Villa, says Emery
-
Emotions high, hope alive after Nigerian school abduction
-
Another original Hermes Birkin bag sells for $2.86 mn
-
11 million flock to Notre-Dame in year since rising from devastating fire
-
Gymnast Nemour lifts lid on 'humiliation, tears' on way to Olympic gold
-
Lebanon president says country does not want war with Israel
-
France takes anti-drone measures after flight over nuclear sub base
-
Signing up to DR Congo peace is one thing, delivery another
US greenlights pig kidney transplant trials
Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their gene-edited pig kidneys for human transplants.
United Therapeutics along with another company, eGenesis, have been working since 2021 on experiments implanting pig kidneys into humans: initially brain-dead patients and more recently living recipients.
Advocates hope the approach will help address the severe organ shortage. More than 100,000 people in the United States are awaiting transplants, including over 90,000 in need of kidneys.
United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if the trial succeeds.
The study authorization was hailed as a "significant step forward in our relentless mission to expand the availability of transplantable organs," by Leigh Peterson, the company's executive vice president.
The trial will initially enroll six patients with end-stage renal disease before expanding to as many as 50, United Therapeutics said in a statement. The first transplant is expected in mid-2025.
Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study.
"The study will evaluate patients with kidney failure who are listed for a transplant but who face a low probability of receiving a deceased donor offer within a five-year timeframe," the company said.
Xenotransplantation -- transplanting organs from one species to another -- has been a tantalizing yet elusive goal for science.
Early experiments in primates faltered, but advances in gene editing and immune system management have brought the field closer to reality.
Pigs have emerged as ideal donors: they grow quickly, produce large litters, and are already part of the human food supply.
United Therapeutics said trial patients would be monitored for life, assessing survival rates, kidney function, and the risk of zoonotic infections -- diseases that jump from animals to humans.
Currently, there is only one living human recipient of a pig organ: Towana Looney, a 53-year-old from Alabama who received a United Therapeutics kidney on November 25, 2024.
She is also the longest-surviving recipient, having lived with a pig kidney for 71 days as of Tuesday. David Bennett of Maryland received a pig heart in 2022 and survived 60 days.
J.Horn--BTB